Key result
The COMPASS-CAT risk assessment model successfully stratified outpatients on chemotherapy, with 6-month VTE rates of 13.3% in high-risk patients compared to 1.7% in low/intermediate-risk patients.
Why the study?
Can the COMPASS-CAT risk assessment model accurately stratify the risk of venous thromboembolism in outpatients on chemotherapy for common solid tumors?
Population
1,023 outpatients on chemotherapy for breast, colorectal, lung, or ovarian cancer. Excluded: patients on low…
Design
Cohort
Follow-up
6 months
Authors
Loading...
May support COMPASS-CAT for VTE stratification in chemotherapy outpatients; leaves open prospective validation before practice change.
Cohort (n=1,023)
Can the COMPASS-CAT risk assessment model accurately stratify the risk of venous thromboembolism in outpatients on chemotherapy for common solid tumors?
Absolute Event Rate: 13.3% vs 1.7%
The COMPASS-CAT risk assessment model provides a robust tool to stratify VTE risk in outpatients undergoing chemotherapy for common solid tumors, identifying a high-risk group with a 13.3% VTE rate at 6 months.
Gerotziafas et al. (2017) conducted a cohort in Breast, colorectal, lung, or ovarian cancer (n=1,023). High-risk stratification by COMPASS-CAT RAM vs. Low/intermediate-risk stratification was evaluated on Documented symptomatic VTE. The COMPASS-CAT risk assessment model successfully stratified outpatients on chemotherapy, with 6-month VTE rates of 13.3% in high-risk patients compared to 1.7% in low/intermediate-risk patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: